TY - JOUR
T1 - Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
AU - Mathiesen, Caroline Benedicte Kjærulff
AU - Lavrsen, Kirstine
AU - Pedersen, Anders Elm
AU - Wandall, Hans H.
AU - Rasch, Morten G.
AU - Woetmann, Anders
AU - Ødum, Niels
AU - Mandel, Ulla
AU - Clausen, Henrik
N1 - Funding Information: Acknowledgments We would like to express our gratitude for the exceptional laboratory support provided by Karin U. Hansen. We thank Joyce Taylor-Papadimitriou and Joy Burchell for the generous gift of mAb HMFG2. This project was supported by the Novo Nordisk Foundation, the Danish Medical Research Council, the Danish Cancer Research Foundation, the Agnes and Poul Friis Foundation, the Danish Cancer Society, the University of Copenhagen (Program of Excellence), EU-FP7, Danish Agency for Science, Technology and Innovation (FTP).
PY - 2013/4/30
Y1 - 2013/4/30
N2 - Protein glycosylation often changes during cancer development, resulting in the expression of cancer-associated carbohydrate antigens. In particular mucins such as MUC1 are subject to these changes. We previously identified an immunodominant Tn-MUC1 (GalNAc-α-MUC1) cancer-specific epitope not covered by immunological tolerance in MUC1 humanized mice and man. The objective of this study was to determine if mouse antibodies to this Tn-MUC1 epitope induce antibody-dependent cellular cytotoxicity (ADCC) pivotal for their potential use in cancer immunotherapy. Binding affinity of mAb 5E5 directed to Tn-MUC1 was investigated using BiaCore. The availability of Tn-MUC1 on the surface of breast cancer cells was evaluated by immunohistochemistry, confocal microscopy, and flow cytometry, followed by in vitro assessment of antibody-dependent cellular cytotoxicity by mAb 5E5. Biacore analysis demonstrated high affinity binding (KD = 1.7 nM) of mAb 5E5 to its target, Tn-MUC1. Immunolabelling with mAb 5E5 revealed surface expression of the Tn-MUC1 epitope in breast cancer tissue and cell lines, and mAb 5E5 induced ADCC in two human breast cancer cell lines, MCF7 and T47D. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity suggesting that antibodies targeting glycopeptide epitopes on mucins are strong candidates for cancer-specific immunotherapies
AB - Protein glycosylation often changes during cancer development, resulting in the expression of cancer-associated carbohydrate antigens. In particular mucins such as MUC1 are subject to these changes. We previously identified an immunodominant Tn-MUC1 (GalNAc-α-MUC1) cancer-specific epitope not covered by immunological tolerance in MUC1 humanized mice and man. The objective of this study was to determine if mouse antibodies to this Tn-MUC1 epitope induce antibody-dependent cellular cytotoxicity (ADCC) pivotal for their potential use in cancer immunotherapy. Binding affinity of mAb 5E5 directed to Tn-MUC1 was investigated using BiaCore. The availability of Tn-MUC1 on the surface of breast cancer cells was evaluated by immunohistochemistry, confocal microscopy, and flow cytometry, followed by in vitro assessment of antibody-dependent cellular cytotoxicity by mAb 5E5. Biacore analysis demonstrated high affinity binding (KD = 1.7 nM) of mAb 5E5 to its target, Tn-MUC1. Immunolabelling with mAb 5E5 revealed surface expression of the Tn-MUC1 epitope in breast cancer tissue and cell lines, and mAb 5E5 induced ADCC in two human breast cancer cell lines, MCF7 and T47D. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity suggesting that antibodies targeting glycopeptide epitopes on mucins are strong candidates for cancer-specific immunotherapies
KW - clinical assessment methods, lab technology and radiography
KW - ADCC
KW - Immunotherapy
KW - antibodies
KW - cancer
UR - https://www.scopus.com/pages/publications/84876473766
U2 - 10.1007/s10719-012-9437-7
DO - 10.1007/s10719-012-9437-7
M3 - Journal article
SN - 0282-0080
VL - 30
SP - 227
EP - 236
JO - Glycoconjugate Journal
JF - Glycoconjugate Journal
IS - 3
M1 - 22878593
ER -